• HL Genomics corrected its second-plant investment start date to Oct. 30, 2026, from Aug. 24, 2026, following final industrial-complex approval.
• The KRW 54.85 billion investment remains unchanged, representing 45.42% of equity, to expand production capacity.
• Completion remains scheduled for Jan. 15, 2028.
• The investment excludes approximately KRW 12.1 billion already spent on land acquisition and related costs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HL Genomics Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030901399), on October 30, 2026, and is solely responsible for the information contained therein.